These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 15642076

  • 21. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 22. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 23. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [Abstract] [Full Text] [Related]

  • 26. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T, Råstam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, Moeller J, Deiss D.
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [Abstract] [Full Text] [Related]

  • 27. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.
    Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 29. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 30. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 31. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM.
    Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609
    [Abstract] [Full Text] [Related]

  • 32. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar 03; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 33. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec 03; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of glycemic control using NPH insulin sliding scale versus insulin aspart sliding scale in continuously tube-fed patients.
    Cook A, Burkitt D, McDonald L, Sublett L.
    Nutr Clin Pract; 2009 Dec 03; 24(6):718-22. PubMed ID: 19955549
    [Abstract] [Full Text] [Related]

  • 35. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.
    Nutr Metab Cardiovasc Dis; 2001 Jun 03; 11(3):168-75. PubMed ID: 11590992
    [Abstract] [Full Text] [Related]

  • 36. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD, Beck P, Owens DR.
    Horm Metab Res; 2003 Jul 03; 35(7):434-8. PubMed ID: 12931275
    [Abstract] [Full Text] [Related]

  • 37. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.
    Diabetes Obes Metab; 2005 Jan 03; 7(1):73-82. PubMed ID: 15642078
    [Abstract] [Full Text] [Related]

  • 38. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.
    Diabetologia; 2004 Apr 03; 47(4):622-9. PubMed ID: 15298338
    [Abstract] [Full Text] [Related]

  • 39. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.
    Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U.
    Exp Clin Endocrinol Diabetes; 2003 Apr 03; 111(2):97-103. PubMed ID: 12746761
    [Abstract] [Full Text] [Related]

  • 40. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan 03; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.